10:44 AM EDT, 05/17/2024 (MT Newswires) -- Marinus Pharmaceuticals ( MRNS ) said Friday that it has completed enrollment in a phase 3 trial of oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex in children and adults.

The company said that it expects topline data in the first half of Q4 and plans to submit a supplemental new drug application to the US Food and Drug Administration in April next year with a priority review requested.

The firm also said that the US Patent and Trademark Office granted a new method of use patent for ganaxolone in the treatment of tuberous sclerosis complex, expiring in 2040.

Shares of Marinus rose past 3% in recent trading.

Price: 1.34, Change: +0.04, Percent Change: +3.08